Loading
The oral HER2-selective kinase inhibitor zongertinib shrank tumours in about seven in ten patients with previously treated HER2-mutant lung cancer with little of the diarrhoea and rash that plagued earlier HER2 pills, becoming the first oral drug approved for this driver.
Phase 1a/1b study; the primary cohort treated 75 patients with previously treated HER2 tyrosine kinase domain-mutant advanced non-small-cell lung cancer with zongertinib 120 mg daily.
Objective response was 71 percent with a median progression-free survival of 12.4 months, intracranial activity in patients with brain metastases, and mainly low-grade diarrhoea and rash; a separate cohort showed activity after prior trastuzumab deruxtecan.
Zongertinib gives HER2-mutant lung cancer an oral targeted option with brain activity, used after platinum chemotherapy and increasingly before or after trastuzumab deruxtecan.
Shares Lung cancer roadmap: from Doll and Hill and the naming of tobacco, through the cytotoxic plateau, computed tomography screening, EGFR and ALK, immunotherapy by PD-L1, the perioperative trials and PACIFIC, to DLL3 in small-cell disease and a 2032 registry watch, New England Journal of Medicine.
Shares HER2-mutant non-small-cell lung cancer, New England Journal of Medicine.
Shares Beamion LUNG-1, HER2-mutant non-small-cell lung cancer.
Shares Lung cancer roadmap: from Doll and Hill and the naming of tobacco, through the cytotoxic plateau, computed tomography screening, EGFR and ALK, immunotherapy by PD-L1, the perioperative trials and PACIFIC, to DLL3 in small-cell disease and a 2032 registry watch, New England Journal of Medicine.
Shares Lung cancer roadmap: from Doll and Hill and the naming of tobacco, through the cytotoxic plateau, computed tomography screening, EGFR and ALK, immunotherapy by PD-L1, the perioperative trials and PACIFIC, to DLL3 in small-cell disease and a 2032 registry watch, New England Journal of Medicine.